Literature DB >> 8006281

Comparison of the effect of heparin and aspirin versus aspirin alone on transient myocardial ischemia and in-hospital prognosis in patients with unstable angina.

D Holdright1, D Patel, D Cunningham, R Thomas, W Hubbard, G Hendry, G Sutton, K Fox.   

Abstract

OBJECTIVES: This study compared the effects of heparin and aspirin versus aspirin alone on transient myocardial ischemia and in-hospital prognosis in patients with unstable angina.
BACKGROUND: Transient myocardial ischemia occurring in patients with unstable angina is associated with an adverse prognosis. Heparin and aspirin are two drugs used frequently in the treatment of this condition, but the effect of combination therapy versus aspirin alone on transient myocardial ischemia is unknown.
METHODS: Two hundred eighty-five consecutive patients with unstable angina were randomized to receive either intravenous heparin plus oral aspirin (150 mg once daily) (Group H + A) or aspirin alone (Group A). Patients also received a beta-adrenergic blocking agent, diltiazem and intravenous nitrates. ST segment monitoring was performed for the 1st 48 h of treatment. Patients were followed up for the duration of their in-hospital stay.
RESULTS: One hundred fifty-four patients (30 women, mean [+/- SEM] age 58.3 +/- 0.8 years) received heparin and aspirin (Group H + A), and 131 patients (26 women, mean age 60.6 +/- 0.8 years) received aspirin only (Group A). ST segment monitoring (11,622 h) yielded 244 episodes of transient myocardial ischemia of a total duration of 7,819 min. There were no significant differences between the two treatment arms in the number of patients with transient myocardial ischemia (27 [18%] in Group H + A vs. 31 [24%] in Group A), number of episodes (96 in Group H + A vs. 148 in Group A) or total duration of transient myocardial ischemia (2,911 min in Group H + A vs. 4,908 min in Group A). The incidence of in-hospital myocardial infarction or death was significantly higher in patients with transient myocardial ischemia (53% vs. 22%, p < 0.0001). Five of the six deaths occurred in patients with transient myocardial ischemia. Event-free survival from myocardial infarction or death was similar in both treatment groups. Preadmission therapy with aspirin was associated with a lower in-hospital infarction rate (19% vs. 34%, p = 0.01).
CONCLUSIONS: The presence of transient myocardial ischemia in patients with unstable angina is associated with a significantly higher incidence of myocardial infarction or death in hospital. Combined therapy with heparin and aspirin compared with aspirin alone makes no difference in the development of these events, nor does it reduce the development of transient myocardial ischemia.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8006281     DOI: 10.1016/0735-1097(94)90539-8

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  14 in total

1.  Unstable Angina.

Authors: 
Journal:  Curr Treat Options Cardiovasc Med       Date:  2000-02

2.  A critical review of clinical trials for low-molecular-weight heparin therapy in unstable coronary artery disease.

Authors:  S Husted; R Becker; A Kher
Journal:  Clin Cardiol       Date:  2001-07       Impact factor: 2.882

Review 3.  Recent advances in the management of unstable angina and non-Q-wave myocardial infarction.

Authors:  R P Steeds; K S Channer
Journal:  Br J Clin Pharmacol       Date:  1998-10       Impact factor: 4.335

Review 4.  Recognition and treatment of unstable angina.

Authors:  C Brunelli; P Spallarossa; P Rossettin; S Caponnetto
Journal:  Drugs       Date:  1996-08       Impact factor: 9.546

5.  Current and Future Options for Anticoagulant Therapy in the Acute Management of ACS.

Authors:  Charles V Pollack
Journal:  Curr Treat Options Cardiovasc Med       Date:  2013-02

Review 6.  Low-molecular-weight heparin should replace unfractionated heparin in the management of acute coronary syndromes.

Authors:  P J Zed
Journal:  J Thromb Thrombolysis       Date:  1999-08       Impact factor: 2.300

Review 7.  Low molecular weight heparins and coronary artery disease.

Authors:  P J Zed
Journal:  Curr Cardiol Rep       Date:  2000-01       Impact factor: 2.931

8.  Direct Comparison of Aspirin Plus Hirudin, Aspirin Plus Heparin, and Aspirin Alone Among 12,000 Patients with Acute Myocardial Infarction Not Receiving Thrombolysis: Rationale and Design of the First American Study of Infarct Survival (ASIS-1).

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1995       Impact factor: 2.300

Review 9.  Heparin versus placebo for non-ST elevation acute coronary syndromes.

Authors:  Carlos A Andrade-Castellanos; Luis E Colunga-Lozano; Netzahualpilli Delgado-Figueroa; Kirk Magee
Journal:  Cochrane Database Syst Rev       Date:  2014-06-27

10.  Association of Parenteral Anticoagulation Therapy With Outcomes in Chinese Patients Undergoing Percutaneous Coronary Intervention for Non-ST-Segment Elevation Acute Coronary Syndrome.

Authors:  Ji-Yan Chen; Peng-Cheng He; Yuan-Hui Liu; Xue-Biao Wei; Lei Jiang; Wei Guo; Chong-Yang Duan; Yan-Song Guo; Xiao-Ping Yu; Jun Li; Wen-Sheng Li; Ying-Ling Zhou; Chun-Ying Lin; Jian-Fang Luo; Dan-Qing Yu; Zhu-Jun Chen; Wei Chen; Yi-Yue Chen; Zhi-Qiang Guo; Qing-Shan Geng; Ning Tan
Journal:  JAMA Intern Med       Date:  2019-02-01       Impact factor: 21.873

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.